CNS Pharmaceuticals (NASDAQ:CNSP) Releases Earnings Results, Misses Expectations By $4.78 EPS

CNS Pharmaceuticals (NASDAQ:CNSP) released its quarterly earnings data on Tuesday. The company reported ($10.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.37) by ($4.78), FiscalAI reports.

CNS Pharmaceuticals Stock Up 5.3%

NASDAQ:CNSP traded up $0.12 on Tuesday, reaching $2.39. The company’s stock had a trading volume of 5,088 shares, compared to its average volume of 50,955. CNS Pharmaceuticals has a 12-month low of $2.06 and a 12-month high of $34.80. The stock has a 50 day moving average price of $3.66 and a 200 day moving average price of $6.10. The firm has a market cap of $1.48 million, a price-to-earnings ratio of -0.08 and a beta of 2.70.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of CNS Pharmaceuticals in a research note on Wednesday, January 21st. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $20.00.

Institutional Trading of CNS Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Boothbay Fund Management LLC acquired a new position in CNS Pharmaceuticals in the fourth quarter valued at about $71,000. Ikarian Capital LLC purchased a new position in CNS Pharmaceuticals during the fourth quarter worth about $241,000. Finally, Armistice Capital LLC acquired a new stake in shares of CNS Pharmaceuticals during the second quarter valued at about $335,000. 14.02% of the stock is owned by institutional investors and hedge funds.

CNS Pharmaceuticals Company Profile

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.